Data as updated weekly; from 01 January 2024 to 13 October 2024. Note that data shown here includes laboratory confirmed cases only. The most recent weeks presented in the epidemic curves should be interpreted with caution, as there are delays associated with reporting.

As of 13 October 2024
Cases*
34 030
Lab confirmed cases
6 962
Deaths*
981
Lab confirmed deaths
25
As of 13 October 2024
Lab confirmed cases
1 169
Lab confirmed deaths
0
*Note that cases here refers to all cases, including suspected and laboratory confirmed cases. Laboratory confirmed cases are a subset of all cases. The same applies to deaths and laboratory confirmed deaths. In instances where suspected cases are tested and the laboratory results are negative, these cases are not retrospectively removed from the total case numbers. In the DRC, around 45% of cases were tested, and around 50% of tested cases were positive in 2024.
Data as updated weekly; from 01 January 2022 to 13 October 2024. Note that data shown here refers to laboratory confirmed cases only, and are collected from the continent of Africa, across the WHO African and Eastern Mediterranean regions.
Total lab confirmed cases in 2024
8 540
Total lab confirmed deaths in 2024
33
Countries reporting cases in 2024
18
Total lab confirmed cases
10 944
Total lab confirmed deaths
56
Countries reporting cases
22
Work is ongoing to incorporate suspected cases and deaths of mpox within countries in Africa.
Data as updated monthly; from 01 January 2022 to 30 September 2024
Total lab confirmed cases in September 2024
2 763
Total lab confirmed deaths in September 2024
0
Countries reporting cases in September 2024
47
Total lab confirmed cases in 2024
14 478
Total lab confirmed deaths in 2024
51
Countries reporting cases in 2024
74
Total lab confirmed cases
109 699
Total lab confirmed deaths
236
Countries reporting cases
123
Known clade distribution as of 13 October 2024. Clade detection includes cases associated with local transmission and imported cases. Data is based on a combination of sequencing databanks, published literature, epidemiological links, and communication to WHO since 2022.
Map can be clicked to view on a larger scale

This report provides an overview of the mpox1 epidemiological situation in Africa, on a weekly basis (as of 13 October 2024), as well as the global epidemiological situation on a monthly basis (as of September 2024).
Data in this report are based on global surveillance data collected from 01 January 2022, initiated due to the unprecedented human-to-human spread of monkeypox virus (MPXV) globally occurring in the same year.
On 14 August 2024, under the International Health Regulations (2005), the WHO Director General declared that the increase in mpox cases in the Democratic Republic of the Congo and its expansion to neighboring countries constitutes a Public Health Emergency of International Concern (PHEIC). This spread presents a public health risk to other Member States and requires a coordinated international response.
Based on currently available information, the spread of mpox cases in the Democratic Republic of the Congo is attributed to two main outbreaks - spread of MPXV clade Ia in Equateur and other previously affected provinces of the country, and the spread of clade Ib MPXV in the provinces of North and South Kivu, as well as several clade Ib cases detecrted in Kinshasa. Current sequencing in the country is limited and clade distribution might be broader than what is currently known.
WHO conducted the latest global mpox rapid risk assessment in August 2024. Based on the available information, the risk was assessed as:
Please note that regardless of geographic area, epidemiological context, biological sex, gender identity or sexual behaviour, individual-level risk is largely dependent on individual factors such as exposure risk and immune status.
This report mainly focuses on laboratory confirmed case and deaths2 as defined by WHO’s working case definition published in the Surveillance, case investigation and contact tracing for monkeypox interim guidance. In Africa, laboratory confirmed and suspected cases are both shown where possible. Note that countries3 may use their own case definitions separate from those outlined in the above document.
On of 28 November 2022, WHO recommended using the name mpox as a new name for monkeypox. The words were used synonymously for one year as the term monkeypox was phased out. The virus causing mpox is named monkeypox virus (MPXV).
For the WHO European region, both confirmed and probable cases are included within confirmed case counts and detailed case data.
Throughout this document, any use of the word country should be considered shorthand for a country, area, or territory
This section of the report is jointly authored by the WHO Regional Office for Africa, the WHO Regional Office for the Eastern Mediterranean4 and WHO Headquarters.
Since 1 January 2022, cases of mpox have been reported to WHO from 22 Member States across Africa. As of 13 October 2024 , a total of 10 944 laboratory confirmed cases, including 56 deaths, have been reported to WHO.
In 2024, as of 13 October 2024, 18 countries have reported 8 540 confirmed cases, including 33 deaths. The three countries with the majority of the cases in 2024 are Democratic Republic of the Congo, (n = 6 962), Burundi, (n = 1 169), and Nigeria, (n = 94).
A significant number of suspected mpox cases, that are clinically compatible with mpox remain untested due to limited diagnostic capacity in some African countries and thus never get confirmed. For this reason, we include suspected cases in this section of the report.
In 2024, 15 countries have reported both 39 724 suspected and laboratory tested cases, including 987 suspected and confirmed deaths.
This indicator should be interpreted with caution, as suspected mpox cases are recorded according to varying national case definitions. In some countries, suspected cases that undergo testing are not removed from the count, regardless of whether the test result is positive (confirmed case) or negative (discarded case). Moreover, not all countries have robust surveillance systems for mpox, meaning reported case counts are likely underestimate the extent of community transmission.
Case definitions for some countries can be seen in the case definitions subsection.
The distribution of clades reported in Africa, and the outbreak status of the continent is shown in the maps below. Countries with active transmission are defined as those reporting cases in the past 28 days. The distribution of reported mpox clades in Africa is also shown below. It should be noted that in many cases, sequencing may not capture all circulating clades, leading to under-representation of where clades are circulating.
Maps can be clicked to view on a larger scale.


Note that the six week period used here is relative to the date cases were last reported in each country.

Epidemic curve shown by week for cases reported up to 13 Oct 2024. Note that for the purposes of these epidemic curves, countries with more than one clade present are presented in multiple epidemic curves. The most recent weeks presented in the epidemic curves should be interpreted with caution, as there are delays associated with reporting.

Cases in the DRC are excluded from this figure due to cocirculation of clades Ia and Ib.

Cases in the DRC are excluded from this figure due to cocirculation of clades Ia and Ib.



All cases, including suspected and lab confirmed cases are shown from 2024, in the Democratic Republic of the Congo. We exceptionally highlight the DRC due to the testing shortage in country, where over half of suspected cases do not go on to be tested.

Maps can be clicked to view on a larger scale. Note that data are only shown for Africa - data from elsewhere are reflected in the global sections of the report.




Epidemic curve shown by week for cases reported up to 13 Oct 2024.
All cases, including suspected and laboratory tested cases are shown from 2024 where data are available. In some countries, suspected cases that undergo testing are not removed from the count, regardless of whether the test result is positive (confirmed case) or negative (discarded case).








































This section includes the national case definition used in African countries in order to provide more context for the interpretation of data, especially of suspected cases.
Case definitions for suspected cases are shown for the following countries below:
Suspected Case:
Any person presenting with sudden onset of fever >38.3°C (101°F), intense headaches, adenopathy, back pain, myalgia, and intense weakness, followed 1-3 days later by a vesiculopustular skin rash that develops progressively, often starting on the face (more dense) and then spreading to other parts of the body, including the soles of the feet and palms of the hands.
Confirmed Case:
Any case that has been clinically and epidemiologically diagnosed with mpox and laboratory confirmed.
Suspected case:
A person with sudden onset of high fever followed by a vesiculopustular rash predominantly on the face and present on the palms of the hands and soles of the feet; OR presence of at least 5 smallpox-like scars,
OR
Any person with fever > 38.3 °C (101 F), severe headache, lymphadenopathy, back pain, myalgia, and severe weakness, followed 1-3 days later by a progressive rash that often begins on the face (more dense) and then spreads elsewhere on the body, including the soles of the feet and palms of the hands.
Confirmed case:
Any case for which the clinical and epidemiological diagnosis of mpox has been laboratory confirmed.
Data by country can be downloaded as a csv file by clicking the button below. The data include the number of new cases and deaths reported each week, as well as the total number of cases and deaths reported to date. The data are current as of 13 Oct 2024.
All of the following data in this report are presented in the context of the ongoing global mpox outbreak. The data presented here are based on the most recent complete month of data reported to WHO as of 30 September 2024.
Since 1 January 2022, cases of mpox have been reported to WHO from 123 Member States across all 6 WHO regions. As of 30 September 2024 , a total of 109 699 laboratory confirmed cases and 0 probable cases, including 236 deaths, have been reported to WHO.
As of September 2024, the number of monthly reported new cases has increased by 8%, compared to the previous month. The majority of cases reported in the past month were notified from the African Region (63.6%) and the Region of the Americas (15.5%).
The 10 most affected countries globally since 1 January 2022 are: United States of America (n = 34 063), Brazil (n = 12 722), Spain (n = 8 282), Democratic Republic of the Congo (n = 7 095), France (n = 4 334), Colombia (n = 4 269), Mexico (n = 4 177), The United Kingdom (n = 4 100), Peru (n = 3 948), and Germany (n = 3 932). Together, these countries account for 79.2% of the cases reported globally.
In the most recent month of reporting, 47 countries have reported cases, 28, of which reported an increase in monthly case counts.
In the past month, 1 country reported their first case. Countries which reported their first case in the past month are: Guinea.
Global aggregated data are collected through direct reporting from Member States to WHO and its partners or from official country sources. The below epidemic curve shows the aggregated number of cases by month according to the date of case reporting.
Epidemic curve shown by month for cases reported up to 30 Sep 2024 to avoid showing incomplete months of data.

Epidemic curve shown by month for deaths reported up to 30 Sep 2024 to avoid showing incomplete months of data.

Epidemic curve shown by month for cases reported up to 30 Sep 2024 to avoid showing incomplete months of data. Note different y-axis scales.

Epidemic curve shown by month for deaths reported up to 30 Sep 2024 to avoid showing incomplete months of data. Note different y-axis scales.

Epidemic curve shown by month for cases reported up to 30 Sep 2024 to avoid showing incomplete months of data. Note different y-axis scales.




























































































































In the past twelve months, the number of cases reported monthly has declined substantially from the global peak of 30,988 cases observed in August 2022. In the past twelve months (01 Oct 2023 - 30 Sep 2024):
On average, at the global level, 1 462 cases have been observed monthly
The most affected region was the African Region, where 7 412 cases and 34 deaths have been reported. This is followed by the Region of the Americas (5 476 cases, 10 deaths), and the Western Pacific Region (1 986 cases, 10 deaths)
Epidemic curve shown by month for cases reported up to 30 Sep 2024 to avoid showing incomplete months of data.

Epidemic curve shown by month for deaths reported up to 30 Sep 2024 to avoid showing incomplete weeks of data.

Epidemic curve shown by month for cases reported up to 30 Sep 2024 to avoid showing incomplete weeks of data. Note different y-axis scales.

Epidemic curve shown by month for cases reported up to 30 Sep 2024 to avoid showing incomplete weeks of data. Note different y-axis scales.

Note: Maps can be clicked to view on a larger scale


Epidemic curve shown by month for cases reported up to 30 Sep 2024 to avoid showing incomplete months of data.

Epidemic curve shown by month for cases reported up to 30 Sep 2024 to avoid showing incomplete months of data.



| Total mpox cases, by WHO region | ||||||
| Data as of September 2024 | ||||||
| WHO Region | Total cases1 | Total deaths1 | Cases in Aug 2024 | Cases in Sep 2024 | Monthly % change in cases | Month most recent cases reported |
|---|---|---|---|---|---|---|
| Region of the Americas | 65,877 | 150 | 632 | 427 | −32.0% | Sep 2024 |
| European Region | 28,176 | 9 | 285 | 211 | −26.0% | Sep 2024 |
| African Region | 9,425 | 54 | 1,302 | 1,756 | 35.0% | Sep 2024 |
| Western Pacific Region | 4,379 | 10 | 322 | 352 | 9.3% | Sep 2024 |
| South-East Asia Region | 971 | 11 | 16 | 15 | −6.2% | Sep 2024 |
| Eastern Mediterranean Region | 871 | 2 | 2 | 2 | 0.0% | Sep 2024 |
| 1 From Jan 2022 | ||||||
| Total Mpox cases, by WHO region | |||
| From 1 Jan 2022. Data as of 30 Sep 2024 | |||
| Total Confirmed Cases | Total Probable Cases | Total Deaths | |
|---|---|---|---|
| Region of the Americas | |||
| United States of America | 34,063 | 0 | 63 |
| Brazil | 12,722 | 0 | 16 |
| Colombia | 4,269 | 0 | 0 |
| Mexico | 4,177 | 0 | 35 |
| Peru | 3,948 | 0 | 23 |
| Canada1 | 1,800 | 0 | 0 |
| Chile | 1,464 | 0 | 3 |
| Argentina | 1,219 | 0 | 2 |
| Ecuador | 605 | 0 | 3 |
| Guatemala | 406 | 0 | 1 |
| Bolivia (Plurinational State of) | 266 | 0 | 0 |
| Panama | 242 | 0 | 1 |
| Costa Rica | 225 | 0 | 1 |
| Paraguay | 126 | 0 | 0 |
| Dominican Republic | 110 | 0 | 1 |
| El Salvador | 104 | 0 | 0 |
| Honduras | 44 | 0 | 0 |
| Jamaica | 21 | 0 | 0 |
| Uruguay | 19 | 0 | 0 |
| Venezuela (Bolivarian Republic of) | 12 | 0 | 0 |
| Cuba | 8 | 0 | 1 |
| Martinique | 7 | 0 | 0 |
| Bahamas | 4 | 0 | 0 |
| Trinidad and Tobago | 4 | 0 | 0 |
| Aruba | 3 | 0 | 0 |
| Curaçao | 3 | 0 | 0 |
| Guyana | 2 | 0 | 0 |
| Bermuda | 1 | 0 | 0 |
| Guadeloupe | 1 | 0 | 0 |
| Saint Martin | 1 | 0 | 0 |
| Barbados | 1 | 0 | 0 |
| European Region | |||
| Spain | 8,282 | 0 | 3 |
| France | 4,334 | 0 | 0 |
| The United Kingdom | 4,100 | 0 | 0 |
| Germany | 3,932 | 0 | 0 |
| Netherlands | 1,349 | 0 | 0 |
| Portugal | 1,227 | 0 | 2 |
| Italy | 1,062 | 0 | 0 |
| Belgium | 822 | 0 | 2 |
| Switzerland | 588 | 0 | 0 |
| Austria | 353 | 0 | 1 |
| Israel | 325 | 0 | 0 |
| Sweden | 302 | 0 | 0 |
| Ireland | 253 | 0 | 0 |
| Poland | 225 | 0 | 0 |
| Denmark | 209 | 0 | 0 |
| Norway | 109 | 0 | 0 |
| Greece | 102 | 0 | 0 |
| Czechia | 87 | 0 | 1 |
| Hungary | 85 | 0 | 0 |
| Luxembourg | 61 | 0 | 0 |
| Romania | 48 | 0 | 0 |
| Slovenia | 47 | 0 | 0 |
| Finland | 43 | 0 | 0 |
| Serbia | 40 | 0 | 0 |
| Malta | 37 | 0 | 0 |
| Croatia | 34 | 0 | 0 |
| Iceland | 17 | 0 | 0 |
| Slovakia | 16 | 0 | 0 |
| Türkiye | 12 | 0 | 0 |
| Estonia | 11 | 0 | 0 |
| Bosnia and Herzegovina | 9 | 0 | 0 |
| Bulgaria | 7 | 0 | 0 |
| Lithuania | 6 | 0 | 0 |
| Latvia | 6 | 0 | 0 |
| Gibraltar | 6 | 0 | 0 |
| Cyprus | 5 | 0 | 0 |
| Ukraine | 5 | 0 | 0 |
| Andorra | 4 | 0 | 0 |
| Russian Federation | 4 | 0 | 0 |
| Monaco | 3 | 0 | 0 |
| Georgia | 2 | 0 | 0 |
| Greenland | 2 | 0 | 0 |
| Montenegro | 2 | 0 | 0 |
| Republic of Moldova | 2 | 0 | 0 |
| San Marino | 1 | 0 | 0 |
| African Region | |||
| Democratic Republic of the Congo | 7,095 | 0 | 27 |
| Nigeria | 949 | 0 | 9 |
| Burundi | 853 | 0 | 0 |
| Ghana | 128 | 0 | 4 |
| Central African Republic | 104 | 0 | 2 |
| Côte d’Ivoire | 67 | 0 | 1 |
| Cameroon | 51 | 0 | 5 |
| Uganda | 49 | 0 | 0 |
| Congo | 48 | 0 | 2 |
| Liberia | 30 | 0 | 0 |
| South Africa | 30 | 0 | 3 |
| Kenya | 8 | 0 | 0 |
| Rwanda | 6 | 0 | 0 |
| Benin | 3 | 0 | 0 |
| Gabon | 2 | 0 | 0 |
| Guinea | 1 | 0 | 0 |
| Mozambique | 1 | 0 | 1 |
| Western Pacific Region | |||
| China2 | 2,658 | 0 | 1 |
| Australia | 926 | 0 | 0 |
| Japan | 248 | 0 | 1 |
| Viet Nam | 203 | 0 | 8 |
| Republic of Korea | 168 | 0 | 0 |
| Singapore | 65 | 0 | 0 |
| New Zealand | 53 | 0 | 0 |
| Philippines | 32 | 0 | 0 |
| Cambodia | 13 | 0 | 0 |
| Malaysia | 10 | 0 | 0 |
| Guam | 1 | 0 | 0 |
| New Caledonia | 1 | 0 | 0 |
| Lao People's Democratic Republic | 1 | 0 | 0 |
| South-East Asia Region | |||
| Thailand | 845 | 0 | 10 |
| Indonesia | 88 | 0 | 0 |
| India | 33 | 0 | 1 |
| Sri Lanka | 4 | 0 | 0 |
| Nepal | 1 | 0 | 0 |
| Eastern Mediterranean Region | |||
| Saudi Arabia | 764 | 0 | 0 |
| United Arab Emirates | 28 | 0 | 0 |
| Lebanon | 27 | 0 | 0 |
| Sudan | 19 | 0 | 1 |
| Pakistan | 11 | 0 | 1 |
| Morocco | 6 | 0 | 0 |
| Qatar | 5 | 0 | 0 |
| Egypt | 3 | 0 | 0 |
| Oman | 3 | 0 | 0 |
| Bahrain | 2 | 0 | 0 |
| Jordan | 2 | 0 | 0 |
| Iran (Islamic Republic of) | 1 | 0 | 0 |
| - | |||
| Total | 109,699 | 0 | 236 |
| 1 Date information is unavailable for 45 cases in Canada | |||
| 2 Cases shown include those in mainland China (2157), Hong Kong SAR (68), Taipei (431), and Macao (2) | |||
| Mpox cases in last month, by country | ||||||
| September 2024 | ||||||
| Country | Total cases1 | Total deaths1 | Cases in Aug 2024 | Cases in Sep 2024 | Monthly % change in cases | Month most recent cases reported |
|---|---|---|---|---|---|---|
| Democratic Republic of the Congo | 7,095 | 27 | 1,013 | 1,003 | −1.0% | Sep 2024 |
| Burundi | 853 | 0 | 222 | 622 | 180.0% | Sep 2024 |
| Nigeria | 949 | 9 | 12 | 38 | 220.0% | Sep 2024 |
| Uganda | 49 | 0 | 9 | 38 | 320.0% | Sep 2024 |
| Côte d’Ivoire | 67 | 1 | 33 | 25 | −24.0% | Sep 2024 |
| Central African Republic | 104 | 2 | 6 | 10 | 67.0% | Sep 2024 |
| Liberia | 30 | 0 | 1 | 7 | 600.0% | Sep 2024 |
| Kenya | 8 | 0 | 1 | 6 | 500.0% | Sep 2024 |
| Rwanda | 6 | 0 | 0 | 2 | – | Sep 2024 |
| Cameroon | 51 | 5 | 0 | 1 | – | Sep 2024 |
| Congo | 48 | 2 | 2 | 1 | −50.0% | Sep 2024 |
| Gabon | 2 | 0 | 1 | 1 | 0.0% | Sep 2024 |
| Guinea | 1 | 0 | 0 | 1 | – | Sep 2024 |
| South Africa | 30 | 3 | 2 | 1 | −50.0% | Sep 2024 |
| Benin | 3 | 0 | 0 | 0 | – | Jun 2022 |
| Ghana | 128 | 4 | 0 | 0 | – | May 2023 |
| Mozambique | 1 | 1 | 0 | 0 | – | Oct 2022 |
| 1 From Jan 2022 | ||||||
| Mpox cases in last month, by country | ||||||
| September 2024 | ||||||
| Country | Total cases1 | Total deaths1 | Cases in Aug 2024 | Cases in Sep 2024 | Monthly % change in cases | Month most recent cases reported |
|---|---|---|---|---|---|---|
| Brazil | 12,722 | 16 | 280 | 218 | −22.0% | Sep 2024 |
| United States of America | 34,063 | 63 | 219 | 135 | −38.0% | Sep 2024 |
| Argentina | 1,219 | 2 | 26 | 38 | 46.0% | Sep 2024 |
| Canada | 1,800 | 0 | 63 | 17 | −73.0% | Sep 2024 |
| Mexico | 4,177 | 35 | 31 | 13 | −58.0% | Sep 2024 |
| Peru | 3,948 | 23 | 3 | 3 | 0.0% | Sep 2024 |
| Chile | 1,464 | 3 | 1 | 2 | 100.0% | Sep 2024 |
| Panama | 242 | 1 | 0 | 1 | – | Sep 2024 |
| Aruba | 3 | 0 | 0 | 0 | – | Sep 2022 |
| Bahamas | 4 | 0 | 0 | 0 | – | May 2023 |
| Barbados | 1 | 0 | 0 | 0 | – | Jul 2022 |
| Bermuda | 1 | 0 | 0 | 0 | – | Jul 2022 |
| Bolivia (Plurinational State of) | 266 | 0 | 0 | 0 | – | Feb 2024 |
| Colombia | 4,269 | 0 | 7 | 0 | – | Aug 2024 |
| Costa Rica | 225 | 1 | 0 | 0 | – | Mar 2024 |
| Cuba | 8 | 1 | 0 | 0 | – | Nov 2022 |
| Curaçao | 3 | 0 | 0 | 0 | – | Sep 2022 |
| Dominican Republic | 110 | 1 | 0 | 0 | – | Apr 2024 |
| Ecuador | 605 | 3 | 2 | 0 | – | Aug 2024 |
| El Salvador | 104 | 0 | 0 | 0 | – | Apr 2023 |
| Guadeloupe | 1 | 0 | 0 | 0 | – | Aug 2022 |
| Guatemala | 406 | 1 | 0 | 0 | – | Jan 2024 |
| Guyana | 2 | 0 | 0 | 0 | – | Aug 2022 |
| Honduras | 44 | 0 | 0 | 0 | – | Apr 2023 |
| Jamaica | 21 | 0 | 0 | 0 | – | Mar 2023 |
| Martinique | 7 | 0 | 0 | 0 | – | Jan 2023 |
| Paraguay | 126 | 0 | 0 | 0 | – | May 2023 |
| Saint Martin | 1 | 0 | 0 | 0 | – | Aug 2022 |
| Trinidad and Tobago | 4 | 0 | 0 | 0 | – | Jul 2023 |
| Uruguay | 19 | 0 | 0 | 0 | – | Dec 2022 |
| Venezuela (Bolivarian Republic of) | 12 | 0 | 0 | 0 | – | Dec 2022 |
| 1 From Jan 2022 | ||||||
| Mpox cases in last month, by country | ||||||
| September 2024 | ||||||
| Country | Total cases1 | Total deaths1 | Cases in Aug 2024 | Cases in Sep 2024 | Monthly % change in cases | Month most recent cases reported |
|---|---|---|---|---|---|---|
| Jordan | 2 | 0 | 0 | 1 | – | Sep 2024 |
| Morocco | 6 | 0 | 0 | 1 | – | Sep 2024 |
| Bahrain | 2 | 0 | 0 | 0 | – | Apr 2023 |
| Egypt | 3 | 0 | 0 | 0 | – | Dec 2022 |
| Iran (Islamic Republic of) | 1 | 0 | 0 | 0 | – | Aug 2022 |
| Lebanon | 27 | 0 | 0 | 0 | – | Mar 2023 |
| Oman | 3 | 0 | 0 | 0 | – | Oct 2023 |
| Pakistan | 11 | 1 | 1 | 0 | – | Aug 2024 |
| Qatar | 5 | 0 | 0 | 0 | – | Sep 2022 |
| Saudi Arabia | 764 | 0 | 1 | 0 | – | Aug 2024 |
| Sudan | 19 | 1 | 0 | 0 | – | Apr 2023 |
| United Arab Emirates | 28 | 0 | 0 | 0 | – | Apr 2024 |
| 1 From Jan 2022 | ||||||
| Mpox cases in last month, by country | ||||||
| September 2024 | ||||||
| Country | Total cases1 | Total deaths1 | Cases in Aug 2024 | Cases in Sep 2024 | Monthly % change in cases | Month most recent cases reported |
|---|---|---|---|---|---|---|
| Spain | 8,282 | 3 | 136 | 42 | −69.0% | Sep 2024 |
| The United Kingdom | 4,100 | 0 | 40 | 42 | 5.0% | Sep 2024 |
| France | 4,334 | 0 | 24 | 27 | 12.0% | Sep 2024 |
| Germany | 3,932 | 0 | 23 | 23 | 0.0% | Sep 2024 |
| Netherlands | 1,349 | 0 | 19 | 22 | 16.0% | Sep 2024 |
| Portugal | 1,227 | 2 | 10 | 21 | 110.0% | Sep 2024 |
| Belgium | 822 | 2 | 3 | 8 | 170.0% | Sep 2024 |
| Denmark | 209 | 0 | 1 | 5 | 400.0% | Sep 2024 |
| Italy | 1,062 | 0 | 1 | 5 | 400.0% | Sep 2024 |
| Israel | 325 | 0 | 4 | 4 | 0.0% | Sep 2024 |
| Austria | 353 | 1 | 2 | 3 | 50.0% | Sep 2024 |
| Greece | 102 | 0 | 0 | 3 | – | Sep 2024 |
| Ireland | 253 | 0 | 1 | 3 | 200.0% | Sep 2024 |
| Czechia | 87 | 1 | 3 | 2 | −33.0% | Sep 2024 |
| Lithuania | 6 | 0 | 0 | 1 | – | Sep 2024 |
| Andorra | 4 | 0 | 0 | 0 | – | Aug 2022 |
| Bosnia and Herzegovina | 9 | 0 | 0 | 0 | – | Oct 2022 |
| Bulgaria | 7 | 0 | 0 | 0 | – | May 2024 |
| Croatia | 34 | 0 | 0 | 0 | – | Apr 2024 |
| Cyprus | 5 | 0 | 0 | 0 | – | Aug 2022 |
| Estonia | 11 | 0 | 0 | 0 | – | Sep 2022 |
| Finland | 43 | 0 | 0 | 0 | – | Feb 2024 |
| Georgia | 2 | 0 | 0 | 0 | – | Aug 2022 |
| Gibraltar | 6 | 0 | 0 | 0 | – | Aug 2022 |
| Greenland | 2 | 0 | 0 | 0 | – | Aug 2022 |
| Hungary | 85 | 0 | 0 | 0 | – | Jun 2024 |
| Iceland | 17 | 0 | 0 | 0 | – | Sep 2023 |
| Latvia | 6 | 0 | 0 | 0 | – | Oct 2022 |
| Luxembourg | 61 | 0 | 0 | 0 | – | Feb 2024 |
| Malta | 37 | 0 | 2 | 0 | – | Aug 2024 |
| Monaco | 3 | 0 | 0 | 0 | – | Aug 2022 |
| Montenegro | 2 | 0 | 0 | 0 | – | Aug 2022 |
| Norway | 109 | 0 | 2 | 0 | – | Aug 2024 |
| Poland | 225 | 0 | 2 | 0 | – | Aug 2024 |
| Republic of Moldova | 2 | 0 | 0 | 0 | – | Aug 2022 |
| Romania | 48 | 0 | 1 | 0 | – | Aug 2024 |
| Russian Federation | 4 | 0 | 0 | 0 | – | Jan 2024 |
| San Marino | 1 | 0 | 0 | 0 | – | Oct 2022 |
| Serbia | 40 | 0 | 0 | 0 | – | Sep 2022 |
| Slovakia | 16 | 0 | 0 | 0 | – | Jan 2024 |
| Slovenia | 47 | 0 | 0 | 0 | – | Sep 2022 |
| Sweden | 302 | 0 | 2 | 0 | – | Aug 2024 |
| Switzerland | 588 | 0 | 9 | 0 | – | Aug 2024 |
| Türkiye | 12 | 0 | 0 | 0 | – | Oct 2022 |
| Ukraine | 5 | 0 | 0 | 0 | – | Oct 2022 |
| 1 From Jan 2022 | ||||||
| Mpox cases in last month, by country | ||||||
| September 2024 | ||||||
| Country | Total cases1 | Total deaths1 | Cases in Aug 2024 | Cases in Sep 2024 | Monthly % change in cases | Month most recent cases reported |
|---|---|---|---|---|---|---|
| Thailand | 845 | 10 | 13 | 12 | −7.7% | Sep 2024 |
| India | 33 | 1 | 3 | 3 | 0.0% | Sep 2024 |
| Indonesia | 88 | 0 | 0 | 0 | – | Jun 2024 |
| Nepal | 1 | 0 | 0 | 0 | – | Jun 2023 |
| Sri Lanka | 4 | 0 | 0 | 0 | – | Jun 2023 |
| 1 From Jan 2022 | ||||||
| Mpox cases in last month, by country | ||||||
| September 2024 | ||||||
| Country | Total cases1 | Total deaths1 | Cases in Aug 2024 | Cases in Sep 2024 | Monthly % change in cases | Month most recent cases reported |
|---|---|---|---|---|---|---|
| Australia | 926 | 0 | 245 | 302 | 23.0% | Sep 2024 |
| China | 2,658 | 1 | 63 | 28 | −56.0% | Sep 2024 |
| Philippines | 32 | 0 | 5 | 18 | 260.0% | Sep 2024 |
| Republic of Korea | 168 | 0 | 5 | 2 | −60.0% | Sep 2024 |
| Malaysia | 10 | 0 | 0 | 1 | – | Sep 2024 |
| Singapore | 65 | 0 | 3 | 1 | −67.0% | Sep 2024 |
| Cambodia | 13 | 0 | 0 | 0 | – | Feb 2024 |
| Guam | 1 | 0 | 0 | 0 | – | Sep 2022 |
| Japan | 248 | 1 | 1 | 0 | – | Aug 2024 |
| Lao People's Democratic Republic | 1 | 0 | 0 | 0 | – | Sep 2023 |
| New Caledonia | 1 | 0 | 0 | 0 | – | Jul 2022 |
| New Zealand | 53 | 0 | 0 | 0 | – | Jul 2024 |
| Viet Nam | 203 | 8 | 0 | 0 | – | Jul 2024 |
| 1 From Jan 2022 | ||||||
| Countries reporting cases in September | ||
| Country | New cases | New deaths |
|---|---|---|
| African Region | ||
| Democratic Republic of the Congo | 1,003 | 0 |
| Burundi | 622 | 0 |
| Nigeria | 38 | 0 |
| Uganda | 38 | 0 |
| Côte d’Ivoire | 25 | 0 |
| Central African Republic | 10 | 0 |
| Liberia | 7 | 0 |
| Kenya | 6 | 0 |
| Rwanda | 2 | 0 |
| Cameroon | 1 | 0 |
| Congo | 1 | 0 |
| Gabon | 1 | 0 |
| Guinea | 1 | 0 |
| South Africa | 1 | 0 |
| Western Pacific Region | ||
| Australia | 302 | 0 |
| China | 28 | 0 |
| Philippines | 18 | 0 |
| Republic of Korea | 2 | 0 |
| Malaysia | 1 | 0 |
| Singapore | 1 | 0 |
| Region of the Americas | ||
| Brazil | 218 | 0 |
| United States of America | 135 | 0 |
| Argentina | 38 | 0 |
| Canada | 17 | 0 |
| Mexico | 13 | 0 |
| Peru | 3 | 0 |
| Chile | 2 | 0 |
| Panama | 1 | 0 |
| European Region | ||
| Spain | 42 | 0 |
| The United Kingdom | 42 | 0 |
| France | 27 | 0 |
| Germany | 23 | 0 |
| Netherlands | 22 | 0 |
| Portugal | 21 | 0 |
| Belgium | 8 | 0 |
| Denmark | 5 | 0 |
| Italy | 5 | 0 |
| Israel | 4 | 0 |
| Austria | 3 | 0 |
| Greece | 3 | 0 |
| Ireland | 3 | 0 |
| Czechia | 2 | 0 |
| Lithuania | 1 | 0 |
| South-East Asia Region | ||
| Thailand | 12 | 0 |
| India | 3 | 0 |
| Eastern Mediterranean Region | ||
| Jordan | 1 | 0 |
| Morocco | 1 | 0 |
Detailed case data are acquired via direct reporting of case-based data from Member States to WHO. Data from cases are reported1 according to the WHO minimum dataset under the International Health Regulations (IHR 2005) Article 6. Completeness of records is variable, meaning denominators for variables may be different from one another. All of the following is derived from detailed case data, and as a result, overall numbers may not be reflective of figures shown with aggregate case numbers. All detailed cases shown are confirmed cases, where the reporting date occurred after 01 January 2022.
The detailed case dataset was last updated on September 2024. As of this date, the total number of detailed confirmed cases reported is 95 668, representing 87.2% of all aggregated cases reported.
The table below indicates the reporting coverage between reported aggregated confirmed cases and detailed confirmed cases by countries and per region.
| Mpox reporting completeness | |||
| As of 30 Sep 2024 | |||
| Total Confirmed Cases | Total Detailed Confirmed Cases1 | % Detailed Cases reported | |
|---|---|---|---|
| Region of the Americas | 65,877 | 63,943 | 97.1% |
| European Region | 28,176 | 27,944 | 99.2% |
| African Region | 9,425 | 672 | 7.1% |
| Western Pacific Region | 4,379 | 2,902 | 66.3% |
| South-East Asia Region | 971 | 118 | 12.2% |
| Eastern Mediterranean Region | 871 | 89 | 10.2% |
| 1 Note that in rare cases total detailed cases may exceed total confirmed cases due to ongoing data cleaning issues | |||
Trends in cases are shown for all submitted detailed cases. These are shown by:
Reporting of detailed cases is subject to some delay. The epidemic curves shown are not right-censored, and therefore trends in the most recent weeks shown should be interpreted with caution. It should be additionally noted that date of report does not reflect the date of reporting to WHO, but rather reporting to national or regional authorities.
Delay between date of onset and date of diagnosis were calculated for all countries where reporting quality passed criteria. Delays were only shown when the time between onset and diagnosis was between 0 and 50 days.
The median delay between onset and diagnosis was 7 days (interquartile range: 4-10 days)
Data by date of onset and country can be downloaded below.


Note different y-axis scales per country.

Note different y-axis scales per age group

Note that reported sexual behaviour does not necessarily reflect who the case has had recent sexual history with nor does it imply sexual activity. Note different y-axis scales.

Proportion of cases who are men who have sex with men, and proportion of cases who are male are used to monitor the spillover of cases from networks of men who have sex with men to the general population. In both plots below, the denominator is defined as all detailed cases where sexual behavior (above) or sex (below) has been reported. Shaded areas represent 95% confidence intervals.
Note that reported sexual behavior does not necessarily reflect who the case has had recent sexual history with nor does it imply sexual activity.


Select country of interest from the dropdown link below:






































































































As of 30 Sep 2024, the vast majority of cases for which detailed case based data are available are not associated with the outbreak of clade Ib, or the African region. For this reason the following analysis is overwhelmingly reflective of the global situation outside of Africa and clade Ib.
Key features of these cases are as follows:
96.4% (87 957/91 289) of cases with available data are male, the median age is 34 years (IQR: 29 - 41).
Males between 18-44 years old continue to be disproportionately affected by this outbreak as they account for 79.2% of reported cases.
Of all cases with available data, 3.6% (3 332/91 289) are female:
The majority of these cases are reported from the Region of the Americas (2 518/3 332; 76%) and the European Region (463/3 332; 14%)
The most commonly reported form of transmission is via sexual encounters (259/504; 51%)
Of the 95 240 cases where age was available, there were 1 210 (1.3%) cases reported aged 0-17, out of which 346 (0.4%) were aged 0-4:
59 cases were reported to be pregnant or recently pregnant. Of these:
3, 12, and 9 cases were in their first, second, and third trimesters respectively. 32 were in an unknown trimester, and 0 were six weeks or less post-partum.
The median age was 27 years old (IQR: 22 - 31).
13 of these cases were known to be hospitalized. 0 were known to be admitted to ICU and 0 were known to have died.
The most common mode of transmission was sexual encounter (4/7 cases where route was known).
Among cases with known data on sexual behaviour, 85.0% (23 389/27 530) identified as men who have sex with men.
Among those with known HIV status, 51.8% (18 498/35 716) were people living with HIV. Note that information on HIV status is not available for the majority of cases.
1 367 cases were reported to be health workers. However, most were exposed in the community and further investigation is ongoing to determine which were due to occupational exposure.
Of all reported types of transmission, a sexual encounter was reported most commonly, with 19 131 of 22 699 (84.3%) of all reported transmission events.
Of all settings in which cases were likely exposed, the most common was in party setting with sexual contacts, with 4 416 of 6 436 (68.6%) of all reported exposure events.
As of 6 October 2023, the updated case reporting form no longer requires collection of exposure setting as an aspect of the case-based data. While we longer receive this information, we continue to present these data for the historical record.
Note that the proportions shown below should be interpreted with caution. In some cases, a variable may be more likely to be filled in if the answer is yes than if the answer is no. This is most likely to be true for variables such as HIV status, health worker status, travel history, hospitalization, ICU, and death.
| Case profiles | |||
| As of 30 Sep 2024 | |||
| Reported values | Unknown or Missing Value | ||
|---|---|---|---|
| Yes | No | ||
| Men who have sex with men | 23,389 (85.0%) | 4,141 (15.0%) | 68,129 |
| Persons living with HIV | 18,498 (51.8%) | 17,218 (48.2%) | 59,943 |
| Health worker | 1,367 (4.0%) | 32,434 (96.0%) | 61,858 |
| Travel History | 4,125 (15.8%) | 22,062 (84.2%) | 69,472 |
| Sexual Transmission | 19,130 (84.3%) | 3,568 (15.7%) | 72,961 |
| Hospitalized1 | 6,269 (11.0%) | 50,895 (89.0%) | 38,495 |
| ICU | 50 (0.3%) | 15,477 (99.7%) | 80,132 |
| Died | 151 (0.3%) | 58,702 (99.7%) | 36,806 |
| 1 May be hospitalized for isolation or medical treatment | |||

Note different x-axis scales.

Note that some cases represented below may be hospitalized for isolation rather than treatment purposes.



Transmission data were available for 22 699/95 668 (23.7%) of cases.
Transmission can occur during sex via skin-to-skin contact as well as via bodily fluids. While skin-to-skin contact with lesions remains an important transmission route, monkeypox virus has been isolated from semen samples and rectal swabs from confirmed cases. Note that person to person contact excludes known sexual, healthcare-associated, and mother to child transmission.

Exposure setting data were available for 7 692/95 668 (8.0%) of cases.
Note that multiple exposure settings can be attributed to a single case. Here, differentiation between party settings and large events is determined by size of the event, although there is no formal size threshold to distinguish the two.


As of this date in time, with regards to the outbreak of clade IIb, the multi-country mpox outbreak has been overwhelmingly concentrated in sexual networks of men who have sex with men. For this reason, understanding events in which individuals having other sexual behaviours have acquired mpox is important to monitor potential of sustained spillover into the general population. Note that the demographics of cases affected with clade Ib are not represented here.
The following outputs apply to cases with sexual behaviour reported as other than men who have sex with men. As above, note that reported sexual behaviour does not necessarily reflect persons who the case has had recent sexual history with nor does it imply sexual activity.
76.8% (3 072/4 002) of cases with available data are male; the median age is 32 years (IQR: 26-41).
Males between 18-44 years old account for 61.8% of cases.
Among those with known HIV status 24.1% (757/3 145) were people living with HIV. Note that information on HIV status is not available for the majority of cases.
95 cases were reported to be health workers. However, most were exposed in the community.
Of all reported types of transmission, sexual encounter was reported most commonly, with 455 of 880 (51.7%) of all reported transmission events.
Of all settings in which cases were likely exposed, the most common was in households, with 57 of 151 (37.7%) of all likely exposure categories.
Note that the proportions shown below should be interpreted with caution. In some cases, a variable may be more likely to be filled in if the answer is yes than if the answer is no. This is most likely to be true for variables such as HIV status, health worker status, travel history, hospitalization, ICU, and death.
| Case profiles (excluding men who have sex with men) | |||
| As of 30 Sep 2024 | |||
| Reported values | Unknown or Missing Value | ||
|---|---|---|---|
| Yes | No | ||
| Men who have sex with men | 0 | 4,141 (100.0%) | 0 |
| Persons living with HIV | 757 (24.1%) | 2,388 (75.9%) | 996 |
| Health worker | 95 (6.3%) | 1,404 (93.7%) | 2,642 |
| Travel History | 233 (13.1%) | 1,542 (86.9%) | 2,366 |
| Sexual Transmission | 455 (51.7%) | 425 (48.3%) | 3,261 |
| Hospitalized1 | 274 (12.8%) | 1,875 (87.2%) | 1,992 |
| ICU | 13 (1.2%) | 1,063 (98.8%) | 3,065 |
| Died | 10 (0.4%) | 2,515 (99.6%) | 1,616 |
| 1 May be hospitalized for isolation or medical treatment | |||
Transmission data were available for 880/4 141 (21.3%) of cases.
Transmission can occur during sex via skin-to-skin contact as well as via bodily fluids. While skin-to-skin contact with lesions remains an important transmission route, monkeypox virus has been isolated from semen samples and rectal swabs from confirmed cases. Note that person to person contact excludes known sexual, healthcare-associated, and mother to child transmission.



Exposure setting data were available for 152/4 141 (3.7%) of cases that were not men who have sex with men.
Note that multiple exposure settings can be attributed to a single case. Here, differentiation between party settings and large events is determined by size of the event, although there is no formal size threshold to distinguish the two.



This section of the report pertains specifically to the most recent six months of the outbreak, and case report forms that were reported in that time period (01 Apr 2024 - 30 Sep 2024).
In the last six months:
Of all cases with available information, 98% (2 032 / 2 081) of cases were male, and 88% (264 / 300) reported being as men who have sex with men.
Of all reported types of transmission, a sexual encounter was reported most commonly, with 430 of 452 (95.1%) of all reported transmission events.
Note that the proportions shown below should be interpreted with caution. In some cases, a variable may be more likely to be filled in if the answer is yes than if the answer is no. This is most likely to be true for variables such as HIV status, health worker status, travel history, hospitalization, ICU, and death.
| Case profiles | |||
| From 01 Apr 2024 to 30 Sep 2024 | |||
| Reported values | Unknown or Missing Value | ||
|---|---|---|---|
| Yes | No | ||
| Men who have sex with men | 264 (88.0%) | 36 (12.0%) | 1,868 |
| Persons living with HIV | 237 (44.7%) | 293 (55.3%) | 1,638 |
| Health worker | 21 (2.9%) | 704 (97.1%) | 1,443 |
| Travel History | 117 (20.3%) | 458 (79.7%) | 1,593 |
| Sexual Transmission | 430 (95.1%) | 22 (4.9%) | 1,716 |
| Hospitalized1 | 138 (10.0%) | 1,238 (90.0%) | 792 |
| ICU | 1 (0.4%) | 275 (99.6%) | 1,892 |
| Died | 1 (0.1%) | 1,236 (99.9%) | 931 |
| 1 May be hospitalized for isolation or medical treatment | |||

Transmission data were available for 452/2 168 (20.8%) of cases.
Transmission can occur during sex via skin-to-skin contact as well as via bodily fluids. While skin-to-skin contact with lesions remains an important transmission route, monkeypox virus has been isolated from semen samples and rectal swabs from confirmed cases. Note that person to person contact excludes known sexual, healthcare-associated, and mother to child transmission.

Although most cases in current outbreaks have presented with mild disease symptoms, monkeypox virus (MPXV) may cause severe disease in certain population groups (young children, pregnant women, immunosuppressed persons).
Among the cases who reported at least one symptom, the most common symptom is any rash and is reported in 88% of cases with at least one reported symptom. Note that identifying true denominators for symptomatology is difficult due to a general lack of negative reporting and symptom definitions that may vary between countries’ reporting systems.
A bar chart and table showing symptoms is shown below. Here any rash refers to one or more rash symptoms (systemic, oral, genital, or unknown location), and any lymphadenopathy refers to either general or local lymphadenopathy. Systemic rash included rash on the body, excluding mucosal and genital rash. Symptom information is shown for all cases where information was available reported from January 2022.



| Summary of symptoms | |||
| As of 30 Sep 2024 | |||
| All | Male | Female | |
|---|---|---|---|
| Any rash | 32,086 (88.0%) | 29,756 (88.5%) | 1,104 (81.8%) |
| Fever | 20,400 (55.9%) | 19,519 (58.1%) | 710 (52.6%) |
| Systemic rash | 18,451 (50.6%) | 17,513 (52.1%) | 903 (67.0%) |
| Genital rash | 18,216 (49.9%) | 16,704 (49.7%) | 378 (28.0%) |
| Any lymphadenopathy | 10,177 (27.9%) | 9,894 (29.4%) | 222 (16.4%) |
| Headache | 9,806 (26.9%) | 9,255 (27.5%) | 500 (37.0%) |
| Muscle ache | 9,492 (26.0%) | 8,334 (24.8%) | 381 (28.2%) |
| General lymphadenopathy | 8,257 (22.6%) | 8,051 (23.9%) | 146 (10.8%) |
| Fatigue | 6,398 (17.5%) | 6,237 (18.5%) | 155 (11.5%) |
| Sore throat | 5,368 (14.7%) | 5,092 (15.1%) | 225 (16.7%) |
| Local lymphadenopathy | 5,217 (14.3%) | 5,090 (15.1%) | 126 (9.3%) |
| Rash, unknown location | 3,535 (9.7%) | 3,508 (10.4%) | 25 (1.9%) |
| Oral rash | 2,936 (8.0%) | 2,622 (7.8%) | 83 (6.1%) |
| Chills | 2,290 (6.3%) | 2,144 (6.4%) | 112 (8.4%) |
| Cough | 806 (2.2%) | 736 (2.2%) | 55 (4.1%) |
| Vomiting | 776 (2.1%) | 682 (2.0%) | 50 (3.7%) |
| Lymphadenopathy, location unknown | 466 (1.3%) | 452 (1.3%) | 14 (1.0%) |
| Anogenital pain and/or bleeding | 388 (1.1%) | 382 (1.1%) | 6 (0.4%) |
| Asymptomatic | 286 (0.8%) | 261 (0.8%) | 17 (1.3%) |
| Other | 253 (0.7%) | 249 (0.7%) | 5 (0.4%) |
| Conjunctivitis | 205 (0.6%) | 166 (0.5%) | 14 (1.0%) |
| Diarrhea | 119 (0.3%) | 97 (0.3%) | 2 (0.1%) |
| Genital oedema | 45 (0.1%) | 44 (0.1%) | 0 |
MPXV genetic sequences are routinely shared within NCBI GenBank and GISAID databases. Based on mutations and phylogenetic clustering, MPXV is currently divided into two major clades, clade I (one, formally Congo Basin clade) and clade II (two, formally West Africa clade). Each of these clades is further subdivided into two subclades: clade Ia and clade Ib within clade I; clade IIa and clade IIb within clade II.
Clade Ia circulates within multiple countries in Central Africa and is associated with regular spillover from an animal reservoir(s) with some onward person-to-person transmission. Clade Ia has been sampled in Cameroon, Central African Republic, Congo, Democratic Republic of the Congo, South Sudan and Sudan. Mixing of virus sequences from these countries within the clade Ia phylogenetic tree shows international movement of clade Ia viruses.
Clade Ib has recently emerged in eastern regions of the Democratic Republic of the Congo and is undergoing sustained person-to-person transmission. Recent cases of clade Ib have also been detected in Burundi, India, Kenya, Rwanda, Sweden, Thailand and Uganda. There is limited mutational diversity among clade Ib sequences. However, recent sequences from Kenya, Uganda, Sweden and Thailand share several mutations.
Clade IIa has rarely been isolated in humans with most available genetic sequences coming from animal species. Clade IIb has undergone sustained circulation within humans since at least 2016 and has caused a large ongoing outbreak from 2022 to present. The 2022-24 clade IIb outbreak is currently divided into 33 lineages which enable fine scale tracking.
The following phylogenetic visualisations were generated in R using the ggtree package.
In order to promote a better understanding of the dynamics of the mpox outbreak and to support forecasting work, in 2022, WHO undertook an effort to extract epidemiological parameters (incubation period, serival interval and generation interval) from the literature. The initial literature screening was performed and maintained by the Public Health Agency of Canada (PHAC). The overall search strategy was as follows:
The tables below provide an overview of the most relevant estimates for incubation period and generation interval extracted from the literature where the following criteria are met:
The epidemic parameter tables are no longer updated, as the literature screening is no longer carried out.
| Incubation Period | ||||||||||
| As of 19 Jan 2023 | ||||||||||
| Reference | N | Mean1 | 95% CrI (mean)1 | 95% CI (mean)1 | SD1 | Median1 | 95% CrI (median)1 | IQR1 | Range1 | Distribution |
|---|---|---|---|---|---|---|---|---|---|---|
| Miura et al. [1] | 18 | 8.5 | 6.6 - 10.9 | - | - | - | - | - | - | Log-normal |
| Charniga et al. [2] | 40 | 7.6 | 6.2 - 9.7 | - | 1.8 | 6.4 | 5.1 - 7.9 | - | - | Log-normal |
| Rodríguez et al. [3] | 45 | - | - | - | - | - | - | - | - | - |
| Thornhill et al. [4] | 23 | - | - | - | - | 7.0 | - | - | 3 - 20 | - |
| Català et al. [5] | 77 | - | - | - | - | 6.0 | - | - | 4 - 9 | - |
| Tarín-Vicente et al. [6] | 144 | - | - | - | - | 7.0 | - | 5 - 10 | 1 - 19 | - |
| Guzzetta et al. [7] | 30 | 9.1 | - | 6.5 - 10.9 | - | - | - | - | - | Gamma |
| Mailhe et al. [8] | 112 | - | - | - | - | 6.0 | - | 3 - 8 | - | - |
| Moschese et al. [9] | 16 | - | - | - | - | 11.0 | - | 11 - 16 | - | - |
| Gomez-Garberi et al. [10] | 14 | - | - | - | - | 13.0 | - | - | 3 - 30 | - |
| O'Laughlin et al. [11] | 527 | 7.0 | - | - | - | - | - | 4 - 9 | - | - |
| Angelo et al. [12] | 78 | - | - | - | - | 8.0 | - | 5 - 11 | 2 - 40 | - |
| Madewell et al. [14] | 35 | 5.6 | 4.3 - 7.8 | - | - | - | - | - | - | - |
| Ward et al. [15] | 54 | 7.8 | 6.6 - 9.2 | - | - | - | - | - | - | Weibull |
| Besombes et al. [16] | 29 | - | - | - | - | 7.0 | - | 1 - 13 | 0 - 17 | - |
| Kröger et al. [17] | 209 | 8.2 | - | - | 4.7 | - | - | - | - | Log-normal |
| Source: PHAC | ||||||||||
| 1 Units are in days | ||||||||||
| Serial Interval | |||||||
| As of 19 Jan 2023 | |||||||
| Reference | N | Mean1 | 95% CrI (mean)1 | SD1 | Median1 | 95% CrI (median)1 | Distribution |
|---|---|---|---|---|---|---|---|
| Guo et al. [13] | 21 | 5.6 | 1.7 - 10.4 | 1.5 | 5.5 | 1.4 - 10.4 | - |
| Madewell et al. [14] | 57 | 8.5 | 7.3 - 9.9 | - | - | - | Gamma |
| Ward et al. [15] | 79 | 9.5 | 7.4 - 12.3 | - | - | - | Gamma |
| Miura et al. [18] | 34 | 9.4 | - | 6.2 | - | - | Normal |
| Source: PHAC | |||||||
| 1 Units are in days | |||||||
| Generation Interval | ||||
| As of 19 Jan 2023 | ||||
| Reference | N | Mean1 | 95% CrI1 | Distribution |
|---|---|---|---|---|
| Guzzetta et al. [7] | 16 | 12.5 | 7.5 - 17.3 | Gamma |
| Source: PHAC | ||||
| 1 Units are in days | ||||
The incubation period for monkeypox cases confirmed in the Netherlands, May 2022 ( 658) medRxiv . Miura, Fuminari, van Ewijk, Catharina Else, Backer, Jantien A., Xiridou, Maria, Franz, Eelco, de Coul, Eline Op, Brandwagt, Diederik, van Cleef, Brigitte, van Rijckevorsel, Gini, Swaan, Corien, van den Hof, Susan, Wallinga, Jacco. #volume# (2022): 2022.06.09.22276068–> 10.1101/2022.06.09.22276068 ; http://medrxiv.org/content/early/2022/06/13/2022.06.09.22276068.abstract
Estimating the incubation period of monkeypox virus during the 2022 multi-national outbreak ( 722) medRxiv . Charniga, Kelly, Masters, Nina B., Slayton, Rachel B., Gosdin, Lucas, Minhaj, Faisal S., Philpott, David, Smith, Dallas, Gearhart, Shannon, Alvarado-Ramy, Francisco, Brown, Clive, Waltenburg, Michelle A., Hughes, Christine M., Nakazawa, Yoshinori. #volume# (2022): 2022.06.22.22276713–> 10.1101/2022.06.22.22276713 ; http://medrxiv.org/content/early/2022/06/23/2022.06.22.22276713.abstract
Epidemiologic Features and Control Measures during Monkeypox Outbreak, Spain, June 2022 ( 888) Emerg Infect Dis . Rodríguez, B. S., Herrador, B. R. G., Franco, A. D., Fariñas, M. P. S., Del Amo Valero, J., Llorente, A. H. A., de Agreda, Jpap, Malonda, R. C., Castrillejo, D., Chirlaque López, M. D., Chong, E. J., Balbuena, S. F., García, V. G., García-Cenoz, M., Hernández, L. G., Montalbán, E. G., Carril, F. G., Cortijo, T. G., Bueno, S. J., Sánchez, A. L., Linares Dópido, J. A., Lorusso, N., Martins, M. M., Martínez Ochoa, E. M., Mateo, A. M., Peña, J. M., Antón, A. I. N., Otero Barrós, M. T., Martinez, Mdcp, Jiménez, P. P., Martín, O. P., Rivas Pérez, A. I., García, M. S., Soria, F. S., Sierra Moros, M. J.. 28,2022/07/13 (2022): #pages#–> 10.3201/eid2809.221051 ; https://wwwnc.cdc.gov/eid/article/28/9/22-1051_article
Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022 ( 933) N Engl J Med . Thornhill, J. P., Barkati, S., Walmsley, S., Rockstroh, J., Antinori, A., Harrison, L. B., Palich, R., Nori, A., Reeves, I., Habibi, M. S., Apea, V., Boesecke, C., Vandekerckhove, L., Yakubovsky, M., Sendagorta, E., Blanco, J. L., Florence, E., Moschese, D., Maltez, F. M., Goorhuis, A., Pourcher, V., Migaud, P., Noe, S., Pintado, C., Maggi, F., Hansen, A. E., Hoffmann, C., Lezama, J. I., Mussini, C., Cattelan, A., Makofane, K., Tan, D., Nozza, S., Nemeth, J., Klein, M. B., Orkin, C. M.. 2022/07/23 (2022): #pages#–> 10.1056/NEJMoa2207323 ; #URL#
Monkeypox outbreak in Spain: clinical and epidemiological findings in a prospective cross-sectional study of 185 cases ( 1008) Br J Dermatol . Català, A., Clavo Escribano, P., Riera, J., Martín-Ezquerra, G., Fernandez-Gonzalez, P., Revelles Peñas, L., Simón Gozalbo, A., Rodríguez-Cuadrado, F. J., Guilera Castells, V., De la Torre Gomar, F. J., Comunión Artieda, A., Fuertes de Vega, L., Blanco, J. L., Puig, S., García Miñarro Á, M., Fiz Benito, E., Muñoz-Santos, C., Repiso-Jiménez, J. B., Ceballos-Rodriguez, C., García Rodríguez, V., Castaño Fernández, J. L., Sánchez-Gutiérrez, I., Calvo López, R., Berna-Rico, E., de Nicolás-Ruanes, B., Corella Vicente, F., Tarín Vicente, E. J., Fernández de la Fuente, L., Riera-Martí, N., Descalzo-Gallego, M., Grau-Perez, M., García-Doval, I., Fuertes, I.. 2022/08/03 (2022): #pages#–> 10.1111/bjd.21790 ; #URL#
Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study ( 1074) Lancet . Tarín-Vicente, E. J., Alemany, A., Agud-Dios, M., Ubals, M., Suñer, C., Antón, A., Arando, M., Arroyo-Andrés, J., Calderón-Lozano, L., Casañ, C., Cabrera, J. M., Coll, P., Descalzo, V., Folgueira, M. D., García-Pérez, J. N., Gil-Cruz, E., González-Rodríguez, B., Gutiérrez-Collar, C., Hernández-Rodríguez, Á., López-Roa, P., de Los Ángeles Meléndez, M., Montero-Menárguez, J., Muñoz-Gallego, I., Palencia-Pérez, S. I., Paredes, R., Pérez-Rivilla, A., Piñana, M., Prat, N., Ramirez, A., Rivero, Á., Rubio-Muñiz, C. A., Vall, M., Acosta-Velásquez, K. S., Wang, A., Galván-Casas, C., Marks, M., Ortiz-Romero, P., Mitjà, O.. 2022/08/12 (2022): #pages#–> 10.1016/s0140-6736(22)01436-2 ; #URL#
Early Estimates of Monkeypox Incubation Period, Generation Time, and Reproduction Number, Italy, May-June 2022 ( 1189) Emerg Infect Dis . Guzzetta, G., Mammone, A., Ferraro, F., Caraglia, A., Rapiti, A., Marziano, V., Poletti, P., Cereda, D., Vairo, F., Mattei, G., Maraglino, F., Rezza, G., Merler, S.. 28,2022/08/23 (2022): #pages#–> 10.3201/eid2810.221126 ; https://wwwnc.cdc.gov/eid/article/28/10/22-1126_article
Clinical characteristics of ambulatory and hospitalised patients with monkeypox virus infection: an observational cohort study ( 1238) Clin Microbiol Infect . Mailhe, M., Beaumont, A. L., Thy, M., Le Pluart, D., Perrineau, S., Houhou-Fidouh, N., Deconinck, L., Bertin, C., Ferré, V. M., Cortier, M., C.,De La Porte Des Vaux,, Phung, B. C., Mollo, B., Cresta, M., Bouscarat, F., Choquet, C., Descamps, D., Ghosn, J., Lescure, F. X., Yazdanpanah, Y., Joly, V., Peiffer-Smadja, N.. 2022/08/27 (2022): #pages#–> 10.1016/j.cmi.2022.08.012 ; #URL#
Natural history of Human Monkeypox in individuals attending a sexual health clinic in Milan, Italy ( 1262) J Infect . Moschese, D., Pozza, G., Giacomelli, A., Mileto, D., Cossu, M. V., Beltrami, M., Rizzo, A., Gismondo, M. R., Rizzardini, G., Antinori, S.. 2022/08/26 (2022): #pages#–> 10.1016/j.jinf.2022.08.019 ; #URL#
Genitourinary Lesions Due to Monkeypox ( 1440) Eur Urol . Gomez-Garberi, M., Sarrio-Sanz, P., Martinez-Cayuelas, L., Delgado-Sanchez, E., Bernabeu-Cabezas, S., Peris-Garcia, J., Sanchez-Caballero, L., Nakdali-Kassab, B., Egea-Sancho, C., Olarte-Barragan, E., Ortiz-Gorraiz, M.. 2022/09/13 (2022): #pages#–> 10.1016/j.eururo.2022.08.034 ; #URL#
Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022 ( 1486) MMWR Morb Mortal Wkly Rep . O’Laughlin, K., Tobolowsky, F. A., Elmor, R., Overton, R., O’Connor, S. M., Damon, I. K., Petersen, B. W., Rao, A. K., Chatham-Stephens, K., Yu, P., Yu, Y.. 71,2022/09/16 (2022): 1190–> 10.15585/mmwr.mm7137e1 ; #URL#
Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel Network: a cross-sectional study ( 1748) Lancet Infect Dis . Angelo, K. M., Smith, T., Camprubí-Ferrer, D., Balerdi-Sarasola, L., Díaz Menéndez, M., Servera-Negre, G., Barkati, S., Duvignaud, A., Huber, K. L. B., Chakravarti, A., Bottieau, E., Greenaway, C., Grobusch, M. P., Mendes Pedro, D., Asgeirsson, H., Popescu, C. P., Martin, C., Licitra, C., de Frey, A., Schwartz, E., Beadsworth, M., Lloveras, S., Larsen, C. S., Guagliardo, S. A. J., Whitehill, F., Huits, R., Hamer, D. H., Kozarsky, P., Libman, M.. 2022/10/11 (2022): #pages#–> 10.1016/s1473-3099(22)00651-x ; #URL#
Estimation of the serial interval of monkeypox during the early outbreak in 2022 ( 1895) J Med Virol . Guo, Z., Zhao, S., Sun, S., He, D., Chong, K. C., Yeoh, E. K.. 2022/10/23 (2022): #pages#–> 10.1002/jmv.28248 ; #URL#
Serial interval and incubation period estimates of monkeypox virus infection in 12 U.S. jurisdictions, May - August 2022 ( 2007) medRxiv . Madewell, Zachary, Charniga, Kelly, Masters, Nina, Asher, Jason, Fahrenwald, Lily, Still, William, Chen, Judy, Kipperman, Naama, Bui, David, Shea, Meghan, Saathoff-Huber, Lori, Johnson, Shannon, Harbi, Khalil, Berns, Abby, Perez, Taidy, Gateley, Emily, Spicknall, Ian, Nakazawa, Yoshinori, Gift, Thomas. #volume# (2022): #pages#–> 10.1101/2022.10.26.22281516 ; http://europepmc.org/abstract/PPR/PPR564657 https://doi.org/10.1101/2022.10.26.22281516
Transmission dynamics of monkeypox in the United Kingdom: contact tracing study ( 2069) Bmj . Ward, T., Christie, R., Paton, R. S., Cumming, F., Overton, C. E.. 379,2022/11/03 (2022): e073153–> 10.1136/bmj-2022-073153 ; #URL#
National Monkeypox Surveillance, Central African Republic, 2001-2021 ( 2104) Emerg Infect Dis . Besombes, C., Mbrenga, F., Schaeffer, L., Malaka, C., Gonofio, E., Landier, J., Vickos, U., Konamna, X., Selekon, B., Dankpea, J. N., Von Platen, C., Houndjahoue, F. G., Ouaïmon, D. S., Hassanin, A., Berthet, N., Manuguerra, J. C., Gessain, A., Fontanet, A., Yandoko, E. N.. 28,2022/11/04 (2022): #pages#–> 10.3201/eid2812.220897 ; https://wwwnc.cdc.gov/eid/article/28/12/22-0897_article
Monkeypox outbreak 2022 – an overview of all cases reported to the Cologne Health Department ( 2181) Research Square . Kröger, Sophia Toya, Lehmann, Max Christian, Treutlein, Melanie, Fiethe, Achim, Kossow, Annelene, Küfer-Weiß, Annika, Nießen, Johannes, Grüne, Barbara. #volume# (2022): #pages#–> 10.21203/rs.3.rs-2251751/v1 ; http://europepmc.org/abstract/PPR/PPR570380 https://doi.org/10.21203/rs.3.rs-2251751/v1
Time scales of human monkeypox transmission in the Netherlands ( 2405) medRxiv . Miura, Fuminari, Backer, Jantien, van Rijckevorsel, Gini, Bavalia, Roisin, Raven, Stijn, Petrignani, Mariska, Ainslie, Kylie E. C., Wallinga, Jacco. #volume# (2022): #pages#–> 10.1101/2022.12.03.22283056 ; http://europepmc.org/abstract/PPR/PPR579534 https://doi.org/10.1101/2022.12.03.22283056
With reporting frequencies declining, and with new WHO guidance specifying monthly reporting intervals, it is no longer reliable to present cases by week of report. However, in an effort to retain data availability, we present a record of the acute phase of the 2022-2024 outbreak by reporting week. While the end of the acute phase of the outbreak is not explicitly defined, we present data from 1 January 2022 to 14 April 2023, which corresponds to the week when mpox was no longer considered to be a public health emergency of international concern.
Regional trends are shown below:
Epidemic curve shown by month for cases reported up to 14 April 2023.

Epidemic curve shown by month for deaths reported up to 14 April 2023.

Epidemic curve shown by month for cases reported up to 14 April 2023. Note different y-axis scales.

The WHO 2022-24 mpox global trends report aims to provide frequently updated data visualizations. Caution must be taken when interpreting all data presented, and differences between information products published by WHO, national public health authorities, and other sources using different inclusion criteria and different data cut-off times are to be expected. While steps are taken to ensure accuracy and reliability, all data are subject to continuous verification and change. All counts are subject to variations in case detection, definitions, laboratory testing, and reporting strategies between countries, states and territories.
Data are compiled and shared with WHO by national public health authorities. Data compilation and submission to WHO Headquarters is done by the WHO Regional Offices and WHO Country Offices.
WHO makes no warranties or representations regarding the contents, appearance, completeness, technical specifications, or accuracy of the report. WHO disclaims all responsibility relating to, and shall not be liable for, any use of the report, the results of such use, or the reliance thereon.
WHO reserves the right to make updates and changes to the report without notice, and accepts no liability for any errors or omissions in this regard.
The user of the report is responsible for the interpretation and use of the analysis and outputs performed by the report. The submission of content to the report does not imply WHO’s approval or endorsement of that content, or that the content is appropriate for any purpose or meets any established standard or requirement
Any designations employed or presentation by the user in its use of the app, including tables and maps, do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers and boundaries.
All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).
A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).
© World Health Organization 2024, All rights reserved.
WHO supports open access to the published output of its activities as a fundamental part of its mission and a public benefit to be encouraged wherever possible. Permission from WHO is not required for the use of the WHO Mpox global trends report or data available for download.
The user shall not, in connection with use of the app, state or imply that WHO endorses or is affiliated with the user, its use of the app, or any content, output, or analysis resulting from or related to the app, or that WHO endorses any entity, organization, company, or product.
The use of the WHO emblem / logo by a user of the report in connection with its use is not permitted. For further information, please visit WHO Copyright, Licencing and Permissions.
Suggested citation: 2022-24 Mpox Outbreak: Global Trends. Geneva: World Health Organization, 2024. Available online: https://worldhealthorg.shinyapps.io/mpx_global/ (last cited: [date]).
We gratefully acknowledge the input of national public health staff involved in surveillance activities and data submission to WHO, the WHO regional and country offices for the timely compilation of data, and the European Centre for Disease Prevention and Control (ECDC) for the provision of surveillance data collected via the TESSy platform, as well as external partners who contributed additional insights and contextual information on the data.